Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04417621
Title	Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	melanoma
Therapies	LTT462 + LXH 254 Trametinib Ribociclib
Age Groups:	senior \| child \| adult
Covered Countries	USA \| NOR \| NLD \| ITA \| ISR \| GBR \| FRA \| DEU \| CHE \| BEL \| AUS \| ARG